Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Samsung Bioepis Co., a biosimilar medicine developer under Samsung Group, said Tuesday it has launched its biosimilar product ...

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ...

Larry Sears and Sally Zlotnick Sears recently donated $1 million to the Crohn’s and Colitis Foundation, according to a news release.

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Spring House, Pennsylvania Monday, February 24, 2025, 09:00 Hrs [IST] ...

Coffee by itself does not irritate ulcerative colitis. But this caffeine drink can stimulate the colon, which can be more uncomfortable for those living with the condition. Share on Pinterest ...

Immunic (NASDAQ:IMUX – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Immunic to post earnings of ($0.22) ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.